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Background: Continuous renal replacement therapy (CRRT) is the recommended modality of dialysis for critically ill
patients with hemodynamic instability. Yet there remains significant variability in how CRRT is prescribed and
delivered, and limited evidence-basis to guide practice.
Methods: This is a prospective, multi-center observational study of patients undergoing CRRT. Initial enrollment
phase will occur at 4 academic medical centers in North America over 5 years, with a target enrollment of 2000
patients. All adult patients (18–89 years of age) receiving CRRT will be eligible for inclusion; patients who undergo
CRRT for less than 24 h will be excluded from analysis. Data collection will include patient characteristics at baseline
and at time of CRRT initiation; details of CRRT prescription and delivery, including machine-generated treatment
data; and patient outcomes.
Discussion: The goal of this study is to establish a large comprehensive registry of critically ill adults receiving
CRRT. Specific aims include describing variations in CRRT prescription and delivery across quality domains; validating
quality measures for CRRT care by correlating processes and outcomes; and establishing a large registry for use in
quality improvement and benchmarking efforts. For initial analyses, some particular areas of interest are
anticoagulation protocols; approach to fluid overload; CRRT-related workload; and patient safety.
Trial registration: Registered on ClinicalTrials.gov 1/10/2014: NCT02034448.
Keywords: Acute kidney injury, Critical care, Continuous renal replacement therapy, QualityBackground
Acute kidney injury (AKI) occurs commonly in critically
ill patients, complicating more than half of intensive care
unit (ICU) admissions [1, 2]. About 5–6% of ICU pa-
tients will receive renal replacement therapy (RRT), and
hospital mortality rates in this population approach or
exceed 50% [3–6]. Despite the major clinical significance
of this syndrome, there remains no proven therapy to re-
verse or attenuate established AKI, and care is primarily
supportive, including RRT in severe cases.
For ICU patients, particularly those with hemodynamic
instability, continuous renal replacement therapy (CRRT)
has emerged as the dialysis modality of choice in high-* Correspondence: mheung@umich.edu
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ous arteriovenous hemofiltration over 30 years ago, [7]
CRRT has undergone significant evolution with several
improvements allowing more widespread and routine use.
Advancements include peristaltic pump driven venove-
nous circulation, sophisticated hardware and software en-
gineering for precise application of the prescribed
treatment and enhanced safety and alarms, improved
biocompatibility and other membrane characteristics, re-
gional anticoagulation protocols and enhancements in
user interface. Indeed, for hemodynamically unstable pa-
tients the 2012 Kidney Disease: Improving Global Out-
comes (KDIGO) AKI guidelines suggest using CRRT over
intermittent dialysis options [8]. Compared to standard
intermittent hemodialysis (IHD), CRRT offers advantages
of improved hemodynamic stability, better overall solute
clearance, and better fluid balance [8–10]. Observationalle is distributed under the terms of the Creative Commons Attribution 4.0
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patients initially treated with CRRT compared to
conventional IHD, although this benefit has not been
observed in randomized trials [11].
While the clinical role of CRRT has become well-
established, there exists tremendous variability in how
CRRT is prescribed and delivered [12–14]. The KDIGO
AKI guidelines provide some recommendations, stating
that the target delivered CRRT effluent dose should be
20–25 mL/kg/h, and also suggesting that regional citrate
should be the first-line form of anticoagulation [8]. How-
ever, specific recommendations are lacking for a number
of other important areas, such as CRRT modality, details
of anticoagulation protocols, electrolyte supplementation
practices, or approach to fluid balance. This reflects the
lack of strong evidence upon which to base guidelines,
as most studies examining CRRT practices have been
relatively small and/or single-center. In addition, despite
the high-risk nature of the patient population, very few
studies have examined quality metrics and/or patient
safety related to CRRT practices [15].
Here we describe the protocol for a prospective obser-
vational study focused on CRRT practices in critically ill
adult patients across a network of medical centers in
North America (CRRTnet). Our goal is to develop a
large repository of data regarding CRRT practices and
outcomes, allowing characterization of similarities and
differences in standard CRRT practices across medical
centers. The natural variability in practices between (and
even within) centers will provide the ability to compare
outcomes between different practice patterns and gener-
ate important preliminary data to inform future inter-
ventional trials. In addition, a long-term goal for
CRRTnet is to establish benchmarks for best CRRT
practice for centers both within and outside the study.Methods/design
Study oversight and consent
This study was registered on ClinicalTrials.gov before
initiation of recruitment (identifier NCT02034448). Each
of the initial recruitment centers has received local
institutional review board approval for CRRTnet with a
waiver for informed consent. This waiver was granted
due to the minimal risk nature of this observational
study, as well as the recognition that this study would
not be practical without the waiver. Specifically, since no
interventions are involved, patient recruitment into the
database may occur on a retrospective basis and it would
be inefficient and possibly emotionally distressing to
contact patients or their families for consent after the
fact. Furthermore, it is important to include all CRRT
patients in order to provide an unbiased perspective of
practice patterns and maximize validity of our findings.Ongoing study oversight will be performed by the
CRRTnet registry board, which is chaired by SLG and
comprised of the site principal investigators for each of
the recruitment centers.
Design and setting
This is a prospective, multi-center observational study of
critically ill adults undergoing CRRT. Initial recruitment
is planned at 4 academic medical centers in North
America with significant (>50 patients per year) volume
CRRT use: University of Michigan Health System (Ann
Arbor, MI), University of Alberta Hospital, University of
Alberta (Edmonton, Alberta), University Hospital
London Health Sciences Centre (London, Ontario), and
University of Mississippi Medical Center (Jackson, MS).
Patient population
All subjects in this study will be critically ill adult pa-
tients with AKI receiving CRRT as part of their standard
of care. Inclusion criteria are age ≥ 18 years and
≤89 years. Exclusion criteria are patients who receive
CRRT for less than 24 h, and those who are initiated on
CRRT at an outside hospital prior to transfer in whom
incomplete data are available. For patients who require
multiple courses of CRRT during an admission, only the
data from the first course will be considered. Patients
with pre-existing end-stage renal disease on mainten-
ance dialysis are also excluded.
Data collection
Data will be collected encompassing a wide range of vari-
ables examining patient characteristics at enrollment, de-
scribing daily ICU course, capturing details of CRRT, and
describing patient outcomes. Each participating medical
center utilizes an electronic medical record which will
serve as the primary source for data extraction.
The initial intake form includes demographic vari-
ables, and baseline patient characteristics at the time of
CRRT initiation (Table 1). Fluid balance (in liters) be-
tween the time of ICU admission and CRRT initiation
will be collected and used to calculate percent fluid
overload using the following formula: [16, 17].
%fluid overload = [(total fluid intake (L) – total fluid
output (L))/ICU admission weight (kg)] x 100%. Add-
itional patient clinical data will be updated on a daily
basis to reflect clinical management, severity of illness
and laboratory findings (Table 2). All laboratory values
will be recorded as available, and no laboratory testing
will be requested as part of CRRTnet.
For up to the first 7 days of a patient’s CRRT course,
data regarding CRRT prescription and delivery will be
recorded twice daily (Table 3). For days 8 thru 14, CRRT
data will be captured once daily. Details of the CRRT
prescription will be truncated at 14 days. Each of the
Table 1 Planned data collection at time of enrollment
(CRRT initiation)
Category Data Elements




Comorbidities Components of Charlson Index
ICU Admission Data ICU admission date
Admission source (hospital ward, emergency
department, outside hospital transfer)
Primary condition
Secondary condition
CRRT Initiation Data Clinical indication for CRRT (all that apply)
Time from ICU admission to CRRT initiation
Cumulative fluid balance from ICU initiation
to CRRT initiation
Laboratory Data Serum creatinine at ICU admission
Serum creatinine at CRRT initiation
APACHE II score at ICU admission
CRRT continuous renal replacement theray, ICU intensive care unit
Table 3 Daily CRRT data collection
Category Data Elements
Vascular Access Dialysis catheter position
Dialysis catheter type (acute or tunneled)
Dialysis catheter manufacturer
Dialysis catheter size
Any need for catheter manipulation (e.g.
repositioning, replacement)
CRRT Circuit Any circuit interruptions/replacements
and reasons
Priming solution (new circuits)




CRRT Fluids Type of solution
Modality (dialysate, pre- and/or
post-replacement) and rate
Solution additives
CRRT Dose Prescribed effluent dose
Machine Data Card Delivered effluent dose
Type, number and duration of machine
alarms and interruptions
Filter life
CRRT continuous renal replacement theray
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Prismaflex™ device (Baxter International Inc.) which has
a datacard to which machine treatment data are auto-
matically saved. These data include detailed information
such as pressure measurements, fluid removal, delivered
CRRT effluent dose, and all alarms, interruptions and in-
terventions. Machine treatment data files will be down-
loaded and analyzed for each patient. Each site will de-
identify the patient file using the de-identified patient ID
assigned by the registry database in place of the patient
identifier. The de-identified machine data files will beTable 2 Daily clinical data collection
Category Data Elements
Severity of Illness SOFA score components
Need for mechanical ventilation
Vasopressor requirements (drug and rate)
Fluid Balance Type and volume of fluid intake
Type and volume of recorded outputs
Nutrition Enteral nutrition formula and volume
Parenteral nutrition protein, calories and volume
Laboratory Data Complete blood count: white blood cell count,
hemoglobin, hematocrit, platelets
Metabolic panel: sodium, potassium, chloride,
bicarbonate, blood urea nitrogen, creatinine,
phosphate, magnesium, albumin
Coagulation parameters: INR, PTT, anti-Xa activity
Blood gas: pH, PaO2, PaCO2, lactate, ionized calciumuploaded by the site into the CRRTnet Registry within
each patient’s record. Data is parsed by the application
and stored in the database into select data fields based
on dates and time points for each day the patient is on
CRRT. If the data files cannot be accessed/used, the site
can manually fill in the data fields for the specified time
points with data collected by the medical staff.
Data entry will be performed by trained study staff at
each site, and will be entered into an online system using
a password-protected web-based research interface
(Watermark EDGE, Watermark Research Partners, Inc.).
Electronic data transmission will utilize secure socket
layer (SSL) encryption technology to maintain compliance
with privacy and data security. Data within the Water-
mark EDGE database is protected by Transparent Data
Encryption (TDE) encrypted with the AES-265 Cipher.
Limited Data Set (LDS) will be collected with regards to
specific dates for the following: year of birth, admission
dates, treatment dates, date of discharge or death. For pa-
tient data entry each patient will be de-identified via
assigned unique codes and will not contain direct trace-
able identifiers. This registry complies with the following
as set forth in 45 CFR Parts 160 and 164 (“HIPAA Privacy
Rule”): “Covered Entity” (45 CFR § 160.103), “De-identi-
fied information” (45 CFR § 164.514), “Protected Health
Information (“PHI”)” (45 CFR § 164.103) and “Limited
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utilize the same electronic report forms, with the excep-
tion of measurement units customized to match each cen-
ter’s customary laboratory reporting. For purposes of
analysis all unit values entered by the center will also be
converted and stored in a standardized unit for reporting
in addition to the original entry.Interventions
CRRTnet is strictly an observational study and no
clinical interventions will be performed. In addition, no
biosample collection or storage will occur as part of
CRRTnet.Operational definitions
1. Complete recovery: - Return of serum creatinine
(SCr) to within 50% of baseline. Baseline SCr will be
determined by the order of the following:
i. pre-hospital/outpatient SCr values
ii. lowest available in-hospital SCr (before or after)
receiving CRRT
iii. back calculation for a SCr based on an eGFR 75 mL/
min using the CKD-EPI equation
2. Partial recovery: - No longer receiving RRT but SCr
has not returned to within 50% of baseline.
3. Non-recovery: - Remains dialysis dependent.
All serious adverse events related to CRRT will be re-
corded, with a specific focus on the following
complications:
1. Major bleeding event related to heparin
anticoagulation:
i. Drop in hemoglobin of ≥1.0 g/dL within a 24 h
period, and
ii. Transfusion requirement of ≥2 units packed red
blood cells
2. Development of heparin-induced thrombocytopenia:
i. Fall in platelets of at least 30% and
ii. Positive confirmatory test for heparin-induced
thrombocytopenia (serotonin release assay)
3. Hypocalcemia event related to citrate
anticoagulation:
i. Fall in systemic ionized calcium below 0.8 mmol/L,
and one of the followingii. Worsening hypotension/increasing pressor
requirement, or
iii. Cardiac arrhythmia
All serious adverse events will be reviewed with each
site’s principal investigator to confirm appropriateness
for inclusion.
Primary and secondary outcomes
The primary outcome will be patient survival at ICU
discharge. Patient outcomes will also be recorded at
hospital discharge. Additional outcomes include ICU
and hospital length of stay, renal function recovery dur-
ing hospitalization (defined above), and adverse events
related to CRRT (defined above).
Sample size
Due to the observational nature of CRRTnet, a formal
sample size calculation was not performed. However,
our target recruitment is 2000 patients, which would re-
sult in the largest and most detailed collection of CRRT
patients to date.
Statistical analysis
All descriptive data will be analyzed using standard statis-
tical methods. CRRTnet will assess for potential associa-
tions between patient characteristics, CRRT initiation and
prescription parameters, and patient outcomes (mortality,
length of stay, duration of AKI) using ANOVA (for
normally distributed variables) or Kruskal-Wallis (for
non-normally distributed variables). Multivariate pro-
portional hazards models will be constructed, with initial
inclusion of variables with <0.2 significance in univariate
analyses. Additional analyses of registry data will be devel-
oped based on specific research questions.
Data analyses will be performed by Technomics
Research, LLC (Minneapolis, MN) and guided by the
CRRTnet registry board.
Discussion
Severe AKI remains a common complication of critically
ill patients, and recent studies suggest that the incidence
of dialysis-requiring AKI is increasing [18]. CRRT has
emerged as the recommended dialysis modality for
hemodynamically unstable patients in the ICU, and a re-
cent study demonstrates that CRRT is the most com-
monly used dialysis modality in critically ill patients with
AKI [19]. CRRT provides the advantages of improved
solute and fluid balance control compared to patients on
intermittent therapies. Yet in reality “CRRT” is an um-
brella term that encompasses multiple different modal-
ities and approaches. A high degree of variation exists in
how CRRT is prescribed and delivered between (and
within) medical centers, and there is currently a paucity
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CRRTnet was developed with the goal of establishing
the largest registry of CRRT patients to date, allowing
for comparison of outcomes between a variety of
different CRRT practices.
Ideally, each aspect of therapy would be assessed in
randomized clinical trials. However, given the complex-
ities of critically ill patients and potential difficulties with
recruitment in this population, such an approach may
not be feasible to assess every aspect of CRRT care. As
such, observational studies remain an important tool,
particularly when significant variations in practice natur-
ally exist. As an example, CRRTnet was modeled after
the Prospective Pediatric CRRT registry (ppCRRT) [20].
Over a 4 year period and including 13 centers in the
United States, the ppCRRT enrolled 370 critically ill
children who underwent CRRT and characterized out-
comes in this previously under-described population
[21]. Subsequent studies from ppCRRT explored patient
outcomes related to vascular access, [22] anticoagula-
tion, [23] and nutritional practices [24]. These studies
provided important insight into CRRT practices and out-
comes in children, spurred additional research, and con-
tinue to guide best practices in this population by
informing the KDIGO AKI guidelines. Although there is
significantly more literature regarding CRRT practices in
adults, most of this literature is comprised of relatively
small studies, primarily from single-centers. As such,
there remains a significant need for large, multi-center
studies such as CRRTnet.
Beyond descriptive analyses of patient characteristics
and overall outcomes, we are planning on several com-
parative analyses. One particular area of interest is in the
management of fluid overload. Our data will allow deter-
mination of fluid overload status at time of CRRT initi-
ation, as well as daily fluid balances thereafter. While the
dangers of established fluid overload have been increas-
ing recognized in recent years, [10, 25, 26] there is a
paucity of data examining different approaches to fluid
management utilizing renal replacement therapy. We
will examine rates of fluid removal (e.g. in ml/kg/h) and
fluid overload correction to determine potential impact
on patient outcomes such as renal function recovery and
mortality. We hypothesize that, after adjusting for sever-
ity of illness, higher fluid removal rates will be associated
with lower likelihood of renal recovery.
Another area of particular interest is anticoagulation
to maintain CRRT filter patency. The KDIGO guidelines
suggest regional citrate anticoagulation as the first-line
method in patients without a contraindication. We an-
ticipate that citrate anticoagulation will be associated
with longer circuit life compared to heparin or no antic-
oagulation, a finding that has been observed in a number
of clinical trials [27–30]. However, there is no consensusapproach to citrate anticoagulation; while several differ-
ent protocols have been published, there have been no
comparative trials. Because of existing differences in cit-
rate anticoagulation protocols among CRRTnet centers,
we will be able to compare outcomes between different
protocols.
One novel aspect of CRRTnet is the capture and ana-
lysis of machine data. These data record all machine
measurements to the second, and include pressure mea-
surements (e.g. access and return line pressures, filter
pressures, transmembrane pressures), alarms and re-
sponse to alarms, any changes in prescription (including
blood, dialysate and replacement flow rates), interrup-
tions, and actual delivered therapy. To our knowledge,
this is a relatively untapped source of information, and
one goal of CRRTnet will be to develop algorithms for
processing the information downloaded from the CRRT
machine memory cards. One of the challenges of CRRT
is the complexity of therapy and the increased associated
workload compared to intermittent therapies [31]. By
utilizing the detailed treatment data, we will be able to
characterize alarm frequency and provide more precise
estimates on interface time required to maintain this
therapy. This information may be helpful to administra-
tors in determining nursing models and CRRT educa-
tional programs. In addition, nursing workload can be
considered an important secondary outcome that may
vary between and within centers depending on variations
in CRRT protocol. For example, we hypothesize that re-
gional citrate anticoagulation will be associated with less
workload compared to non-citrate anticoagulation. It
will also be interesting to compare associated workload
between different citrate protocols, especially if circuit
filter life is similar.
An important strength of our study is that we are exam-
ining everyday practices. While findings from controlled
clinical trials can sometimes be difficult to duplicate in the
“real world” setting, we will provide a relatively unfiltered
look. This may be particularly important when examining
adverse events and complications of therapy. Conversely,
it is important to recognize that CRRT is performed at a
relatively high frequency at each of the study sites, which
facilitates development of local expertise and maintenance
of competency. Whether or not similar practices will
result in similar outcomes at smaller centers with lower
volumes is uncertain. Nonetheless, we believe that
CRRTnet will provide important outcomes benchmarks
for centers performing CRRT.
Another important strength of CRRTnet is the ability,
through waiver of consent, to include all eligible partici-
pants. In terms of the practicality of obtaining informed
consent for an observational study in a population similar
to our proposal, much can be learned from the unfortu-
nate experience of the PICARD study investigators where
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for informed consent [32]. Enrollment was poor, with only
52% of eligible patients included, greatly hindering the
generalizability of the results. Patient refusal was infre-
quent at all sites, suggesting that patients themselves did
not have concerns or objections to having their data col-
lected when they were able to be approached directly.
However, refusal by family occurred in almost one fifth of
instances, and the absence of family or appropriate proxy
was listed as a cause for refusing enrollment in as high as
40% at one site. Finally, many patients could not be en-
rolled because of death or discharge before being seen by
study personnel. Thus, countless resources were spent on
conducting an observational trial that missed almost half
the eligible subjects, whose data very likely would have in-
fluenced the results of the study were they included. The
CRRTnet database will be highly generalizable based on
the inclusion of most eligible patients.
Some limitations of our study design are worth noting.
First, we will truncate CRRT data at 14 days, which will
limit applicability in patients on prolonged courses of
CRRT. This decision was made primarily as a feasibility
measure to limit the workload associated with detailed
clinical data collection; importantly, preliminary data
from participating centers showed that median duration
of CRRT was in the range of 6–8 days, so we will still
capture the full CRRT course for the majority of patients
enrolled. Second, we will not be enrolling patients with
AKI who only receive intermittent dialysis therapies and
we recognize that there can be significant variation in
which patients are chosen to undergo CRRT versus
intermittent therapies. However, it is important to note
that our goal is not to establish the role of CRRT in AKI
management, but rather to focus on practice variation
within CRRT prescription and delivery. So while we will
not be able to advocate for which patients should be
managed with CRRT, we hope to inform clinicians of
best practices once a decision to initiate CRRT is made.
Over the past 30 years, CRRT has developed into an im-
portant tool for the management of critically ill patients
with renal failure. Despite overall improvements, there re-
mains marked variation in CRRT practices which is driven
in part by lack of evidence-based guidance. The primary
goal of CRRTnet is to develop a large data repository of
CRRT patients with detailed information regarding spe-
cific CRRT practices which can then be compared in rela-
tion to outcomes. We anticipate that CRRTnet will
provide the nephrology and critical care communities with
an important resource for planning future clinical trials as
well as for benchmarking clinical outcomes.
Trial status
Recruitment is currently active at the 4 medical centers
mentioned above. A fifth center is undergoing evaluationto join CRRTnet. The initial planned recruitment phase
is 5 years with a target enrollment of 2000 patients.
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